Ascendis Pharma ADR (ASND)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2024 | 12-2023 | 09-2023 | 06-2023 | 03-2023 | |
| Sales | 104,112 | 148,657 | 52,280 | 51,677 | 36,054 |
| Cost of Goods | 8,218 | 20,950 | 8,041 | 14,098 | 4,960 |
| Gross Profit | 95,895 | 127,707 | 44,239 | 37,580 | 31,094 |
| Operating Expenses | 149,469 | 167,599 | 190,569 | 191,247 | 186,286 |
| Operating Income | -53,357 | -38,942 | -146,289 | -153,570 | -154,232 |
| Interest Expense | 83,774 | 265 | 26,687 | 10,178 | 10,562 |
| Other Income | -2,411 | -47,556 | -2,886 | 30,869 | 47,131 |
| Pre-tax Income | -139,542 | -86,763 | -175,862 | -132,878 | -117,663 |
| Income Tax | 2,723 | 6,278 | 702 | -468 | 1,392 |
| Net Income Continuous | -142,265 | -93,041 | -176,564 | -132,411 | -119,055 |
| Net Income | $-142,265 | $-93,041 | $-176,564 | $-132,411 | $-119,055 |
| EPS Basic Total Ops | -2.50 | -1.64 | -3.14 | -2.36 | -2.13 |
| EPS Basic Continuous Ops | -2.50 | -1.64 | -3.14 | -2.36 | -2.12 |
| EPS Diluted Total Ops | -2.50 | -1.64 | -3.14 | -2.36 | -2.13 |
| EPS Diluted Continuous Ops | -2.50 | -1.64 | -3.14 | -2.36 | -2.12 |
| EPS Diluted Before Non-Recurring Items | N/A | -1.66 | -3.12 | -2.35 | -2.12 |
| EBITDA(a) | $-48,496 | $-33,641 | $-141,145 | $-148,428 | $-149,352 |